Literature DB >> 24061205

The genetics of NAFLD.

Quentin M Anstee1, Christopher P Day.   

Abstract

NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority experience associated morbidity. As such, NAFLD is best considered a complex disease trait resulting from environmental exposures acting on a susceptible polygenic background and comprising multiple independent modifiers. Much ongoing research is focused on identifying the genetic factors that contribute to NAFLD pathogenesis. This Review describes the current status of the field, discussing specific genetic and epigenetic modifiers, including the mechanisms through which genes identified by genome-wide association studies, including PNPLA3, influence disease progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061205     DOI: 10.1038/nrgastro.2013.182

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  141 in total

Review 1.  Genome-wide association studies for common diseases and complex traits.

Authors:  Joel N Hirschhorn; Mark J Daly
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

2.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

3.  How big a problem is non-alcoholic fatty liver disease?

Authors:  Quentin M Anstee; Stuart McPherson; Christopher P Day
Journal:  BMJ       Date:  2011-07-18

Review 4.  The TDT and other family-based tests for linkage disequilibrium and association.

Authors:  R S Spielman; W J Ewens
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

5.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.

Authors:  Nicola Santoro; Clarence K Zhang; Hongyu Zhao; Andrew J Pakstis; Grace Kim; Romy Kursawe; Daniel J Dykas; Allen E Bale; Cosimo Giannini; Bridget Pierpont; Melissa M Shaw; Leif Groop; Sonia Caprio
Journal:  Hepatology       Date:  2011-12-18       Impact factor: 17.425

6.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Ethnic differences in hepatic steatosis: an insulin resistance paradox?

Authors:  Richard Guerrero; Gloria L Vega; Scott M Grundy; Jeffrey D Browning
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.

Authors:  Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

10.  Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Kikuko Hotta; Yuichi Nozaki; Hiroki Endo; Takashi Uchiyama; Hironori Mawatari; Hiroshi Iida; Shingo Kato; Koji Fujita; Hirokazu Takahashi; Hiroyuki Kirikoshi; Noritoshi Kobayashi; Masahiko Inamori; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Koichiro Wada; Atsushi Nakajima
Journal:  Liver Int       Date:  2009-03-03       Impact factor: 5.828

View more
  106 in total

1.  From nonalcoholic Fatty liver disease to hepatocellular carcinoma: a systems understanding.

Authors:  Damjana Rozman
Journal:  Dig Dis Sci       Date:  2014-02       Impact factor: 3.199

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

4.  Experimental models of non-alcoholic fatty liver disease in rats.

Authors:  Otto Kucera; Zuzana Cervinkova
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 5.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

6.  Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome.

Authors:  D S Sinasac; J D Riordan; S H Spiezio; B S Yandell; C M Croniger; J H Nadeau
Journal:  Int J Obes (Lond)       Date:  2015-09-18       Impact factor: 5.095

7.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

8.  Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.

Authors:  Alexandra Feldman; Sebastian K Eder; Thomas K Felder; Lyudmyla Kedenko; Bernhard Paulweber; Andreas Stadlmayr; Ursula Huber-Schönauer; David Niederseer; Felix Stickel; Simon Auer; Elisabeth Haschke-Becher; Wolfgang Patsch; Christian Datz; Elmar Aigner
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

9.  Systems Analyses Reveal Physiological Roles and Genetic Regulators of Liver Lipid Species.

Authors:  Pooja Jha; Molly T McDevitt; Rahul Gupta; Pedro M Quiros; Evan G Williams; Karim Gariani; Maroun B Sleiman; Leo Diserens; Adam Jochem; Arne Ulbrich; Joshua J Coon; Johan Auwerx; David J Pagliarini
Journal:  Cell Syst       Date:  2018-06-13       Impact factor: 10.304

10.  Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Authors:  Lynda Aoudjehane; Pierre-Yves Boelle; Grégoire Bisch; Rolland Delelo; François Paye; Olivier Scatton; Chantal Housset; Jérôme Becquart; Yvon Calmus; Filomena Conti
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.